This discovery in Cannabis DNA will change how you see weed forever; 33 genetic markers explained
Université Laval
in Québec has made a significant breakthrough in cannabis research and breeding by identifying 33 genetic markers in marijuana that influence the plant's
cannabinoid production
. The discovery opens new doors to developing custom cannabis strains for specific medical and recreational purposes.
Published in the peer-reviewed journal The
Plant Genome
, the study could significantly advance the science of
cannabis cultivation
by allowing breeders to fine-tune the plant's chemical profile with greater precision.
The research team studied 174 cannabis samples and used high-density genotyping to analyze over 23,000 molecular markers. From this dataset, they pinpointed 33 specific markers strongly associated with the production of 11 cannabinoids, compounds like THCA, CBDA, and
CBN
, which are known for their therapeutic and psychoactive properties.
Among the most notable findings was a large cluster of genes on one chromosome region that spans approximately 60 megabases. This region was strongly linked to THC-dominant strains of cannabis, confirming the role of specific DNA segments in driving potency levels.
Live Events
What does this mean for breeders?
Historically, cannabis breeding has been a time-consuming process that involved growing plants to maturity, harvesting them, and analyzing their chemical content. This method can take months and is prone to variability.
The new genetic markers now provide a reliable way to predict cannabinoid content early in the breeding process. This allows breeders to select plants with the desired genetic traits without waiting for full plant maturity. The process becomes faster, cheaper, and more efficient.
'These markers offer powerful tools for improving cannabis through molecular breeding,' the researchers wrote. 'They help overcome barriers that have limited the development of elite strains due to decades of prohibition and lack of genetic infrastructure.'
A boost for medical marijuana
This development is particularly promising for the
medical cannabis
industry. It targets genetic traits responsible for producing non-psychoactive cannabinoids like CBD and CBG, breeders can create strains tailored for pain relief, inflammation, anxiety, epilepsy, and other conditions, without inducing a high.
The ability to develop strains with precise chemical balances can also help standardize dosing, which has long been a challenge in medical marijuana use.
Global research momentum
This study adds to a growing wave of scientific interest in cannabis. Recently, researchers in South Korea identified a new cannabinoid compound, cannabielsoxa, which has sparked further investigation into the plant's unexplored genetic complexity.
As more countries legalize cannabis and invest in research, experts say these kinds of discoveries will become more common and more valuable.
The discovery of these 33 genetic markers marks a significant step toward modernizing cannabis cultivation. As genetic tools become more widely adopted, the industry can expect to see faster development of high-quality, purpose-driven cannabis strains.
Researchers believe that with continued investment in plant genomics, cannabis could soon join other major crops like corn, wheat, and soybeans in benefiting from cutting-edge breeding techniques.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
3 days ago
- NDTV
Cannabis Compounds Show Potential Against Deadly Fungal Pathogen In Lab Studies
Recent laboratory research indicates that compounds derived from the cannabis plant, specifically cannabidiol (CBD) and cannabidivarin (CBDV), exhibit antifungal properties against Cryptococcus neoformans, a WHO-listed priority fungal pathogen responsible for severe infections like cryptococcal meningitis. In vitro studies have shown that these cannabinoids can inhibit the growth of this pathogen, suggesting potential avenues for developing new antifungal treatments. According to a media release by Macquarie University, the compounds also killed dermatophytes that cause common skin infections, and much faster than existing treatments. The study's findings pave the way for potential new treatments for fungal infections. Published in The Journal of Neglected Tropical Diseases (PLOS NTDs), the research offers promising prospects for addressing these infections. Fungal infections affect more than one billion people around the world each year, according to data from the Centres for Disease Control and Prevention. Whether it's athlete's foot, a yeast infection, or the potentially deadly lung infection pneumocystis pneumonia, fungal pathogens are a serious health threat with relatively few effective treatments. Macquarie University's Dr Hue Dinh, a postdoctoral research fellow in the School of Natural Science, and Associate Professor Amy Cain resolved to tackle the growing threat of fungal infections with help from Professor Mark Connor and Dr Marina Junqueira Santiago from the Macquarie School of Medicine and collaborators at the Universities of Sydney and NSW. Having worked in the field of antimicrobial resistance, Dr Hue Dinh knew that developing an entirely new drug and getting it to market could take decades. It made more sense to work with pharmacological compounds already approved for use in humans for other conditions because their safety and mechanism of action are already well known. Cannabis connection Dr Dinh says one of the challenges in the research project was deciding which cannabinoids to test and against what. "Hundreds of natural compounds can be extracted from the cannabis plant, and we don't know which ones work," says Dr Dinh. Macquarie Medical School pharmacologist Professor Mark Connor, who has a strong background in researching cannabinoids, joined the team in their quest to target the fungal pathogen Cryptococcus neoformans, which causes deadly lung or brain infections. "When Cryptococcus neoformans gets to your central nervous system, it causes life-threatening meningitis. The mortality rate is very high, and it's really hard to treat," says Dr Dinh. The researchers found two cannabinoids - cannabidiol and cannabidivarin - that both quickly killed Cryptococcus neoformans in the laboratory, working even faster than current antifungal therapy. They tested the compounds against 33 other fungal pathogens from clinical, veterinary and environmental settings. This revealed the cannabinoids were effective in killing a range of Cryptococcus species as well as the fungal skin pathogens that cause athlete's foot.
Time of India
4 days ago
- Time of India
This discovery in Cannabis DNA will change how you see weed forever; 33 genetic markers explained
Université Laval in Québec has made a significant breakthrough in cannabis research and breeding by identifying 33 genetic markers in marijuana that influence the plant's cannabinoid production . The discovery opens new doors to developing custom cannabis strains for specific medical and recreational purposes. Published in the peer-reviewed journal The Plant Genome , the study could significantly advance the science of cannabis cultivation by allowing breeders to fine-tune the plant's chemical profile with greater precision. The research team studied 174 cannabis samples and used high-density genotyping to analyze over 23,000 molecular markers. From this dataset, they pinpointed 33 specific markers strongly associated with the production of 11 cannabinoids, compounds like THCA, CBDA, and CBN , which are known for their therapeutic and psychoactive properties. Among the most notable findings was a large cluster of genes on one chromosome region that spans approximately 60 megabases. This region was strongly linked to THC-dominant strains of cannabis, confirming the role of specific DNA segments in driving potency levels. Live Events What does this mean for breeders? Historically, cannabis breeding has been a time-consuming process that involved growing plants to maturity, harvesting them, and analyzing their chemical content. This method can take months and is prone to variability. The new genetic markers now provide a reliable way to predict cannabinoid content early in the breeding process. This allows breeders to select plants with the desired genetic traits without waiting for full plant maturity. The process becomes faster, cheaper, and more efficient. 'These markers offer powerful tools for improving cannabis through molecular breeding,' the researchers wrote. 'They help overcome barriers that have limited the development of elite strains due to decades of prohibition and lack of genetic infrastructure.' A boost for medical marijuana This development is particularly promising for the medical cannabis industry. It targets genetic traits responsible for producing non-psychoactive cannabinoids like CBD and CBG, breeders can create strains tailored for pain relief, inflammation, anxiety, epilepsy, and other conditions, without inducing a high. The ability to develop strains with precise chemical balances can also help standardize dosing, which has long been a challenge in medical marijuana use. Global research momentum This study adds to a growing wave of scientific interest in cannabis. Recently, researchers in South Korea identified a new cannabinoid compound, cannabielsoxa, which has sparked further investigation into the plant's unexplored genetic complexity. As more countries legalize cannabis and invest in research, experts say these kinds of discoveries will become more common and more valuable. The discovery of these 33 genetic markers marks a significant step toward modernizing cannabis cultivation. As genetic tools become more widely adopted, the industry can expect to see faster development of high-quality, purpose-driven cannabis strains. Researchers believe that with continued investment in plant genomics, cannabis could soon join other major crops like corn, wheat, and soybeans in benefiting from cutting-edge breeding techniques.
Hindustan Times
29-05-2025
- Hindustan Times
Mainstreaming ecosystem-based adaptation in India
Ecosystem-based adaptation (EbA), recognised for its cost-effective and co-beneficial advantages, is seeing a global uptake. However, the number and scale of EbA projects remain limited compared to the opportunities offered by India's diverse ecosystems and indigenous practices. While lack of funding is a direct cause, the small scale of existing EbA projects also fails to attract funding. Breaking this cycle requires addressing other mechanisms that hinder EbA's growth. This brief explores India's potential and identifies key challenges to scaling up EbA. Ecosystem-based adaptation (EbA), which is part of the broader nature-based solutions (NbS) approach, was defined by the 15th Convention on Biological Diversity (CBD) Conference of the Parties (COP) in 2009 as 'the use of biodiversity and ecosystem services as part of an overall adaptation strategy to help people adapt to the adverse effects of climate change.' The EbA approach aims to enhance resilience by acknowledging the interconnectedness of ecosystem health and human well-being while integrating traditional adaptation methods. It addresses sustainable development goals, climate adaptation and mitigation needs, human rights and well-being, nature conservation, and biodiversity preservation. These co-benefits contribute to its cost-effectiveness compared to engineering-based solutions. Evidence strongly supports this. An overall analysis of the literature shows that NbS and EbA are more cost-effective than engineering-based solutions while still effectively mitigating hazards. Approximately 65% of the studies, most of them in developing countries, indicate that EbA interventions are more effective overall and in specific scenarios. Multiple cost-benefit analysis methods, such as net present value, internal rate of return, and benefit-cost ratio, have been used to assess EbA's socio-economic value. This scientific support, along with advocacy from international organisations like the Global Adaptation Commission and IPCC AR6 report, has promoted the integration of EbA into National Adaptation Plans. Despite this momentum, EbA's growth in India has been slow, even though India's diverse ecosystems, adaptation needs, and indigenous practices provide a basis for EbA projects. To advance EbA in India, its alignment with the nation's goals and challenges must be further explored. This paper can be accessed here. This paper is authored by Diya Shah, ORF, New Delhi.
